ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB FOR BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: MANAGEMENT OF ADVERSE EVENTS FROM A RANDOMIZED, 3-ARM, PHASE 3 STUDY VS. THE CHOICE OF EITHER IRINOTECAN OR FOLFIRI PLUS CETUXIMAB (BEACON CRC)

被引：0
|
作者：
Trevino, Tracy [1 ]
Kopetz, Scott [1 ]
Grothey, Axel [2 ]
Yaeger, Rona [1 ]
Sandor, Victor [3 ]
Velez, Lydia [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] West Canc Ctr & Res Inst, Germantown, TN USA
[3] Pfizer Inc, New York, NY USA
[4] Vail dHebron Univ Hosp, Vail dHebron Inst Oncol, Barcelona, Spain
来源：
ONCOLOGY NURSING FORUM | 2020年 / 47卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
457
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC
    Grothey, A.
    Kopetz, S.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Maharry, K.
    Christy-Bittel, J.
    Gollerkeri, A.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S243 - S243
  • [32] TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.
    Kotani, Daisuke
    Kagawa, Yoshinori
    Matsubara, Yuki
    Bando, Hideaki
    Harada, Kazuaki
    Takahashi, Naoki
    Mihara, Yoshiaki
    Nakayama, Izuma
    Izawa, Naoki
    Kawakami, Takeshi
    Masuishi, Toshiki
    Hasegawa, Hiroko
    Ohta, Takashi
    Wakabayashi, Masashi
    Yoshino, Takayuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS264 - TPS264
  • [33] Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
    Boccaccino, A.
    Borelli, B.
    Intini, R.
    Antista, M.
    Bensi, M.
    Rossini, D.
    Passardi, A.
    Tamberi, S.
    Giampieri, R.
    Antonuzzo, L.
    Noto, L.
    Roviello, G.
    Zichi, C.
    Salati, M.
    Puccini, A.
    Noto, C.
    Parisi, A.
    Rihawi, K.
    Persano, M.
    Crespi, V
    Libertini, M.
    Giordano, M.
    Moretto, R.
    Lonardi, S.
    Cremolini, C.
    [J]. ESMO OPEN, 2022, 7 (03)
  • [34] BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Ciardiello, Fortunato
    Desai, Jayesh
    Kim, Tae Won
    Maughan, Tim
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Edwards, Michelle L.
    Golden, Adele
    Gollerkeri, Ashwin
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
    Trouiller, Jean-Baptiste
    Macabeo, Berengere
    Poll, Andrew
    Howard, Dan
    Buckland, Andy
    Sivignon, Marine
    Clay, Emilie
    Malka, David
    Samalin, Emmanuelle
    Toumi, Mondher
    Laramee, Philippe
    [J]. BMJ OPEN, 2022, 12 (11):
  • [36] A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)
    Kobayashi, S.
    Bando, H.
    Taketomi, A.
    Takamoto, T.
    Shinozaki, E.
    Shiozawa, M.
    Hara, H.
    Yamazaki, K.
    Komori, K.
    Matsuhashi, N.
    Kato, T.
    Kagawa, Y.
    Yokota, M.
    Oki, E.
    Takahashi, S.
    Yoshino, T.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S736 - S737
  • [37] BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
    Van Cutsem, E.
    Cuyle, P.
    Huijberts, S.
    Schellens, J.
    Elez, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Maharry, K.
    Christy-Bittel, J.
    Gollerkeri, A.
    Kopetz, S.
    Grothey, A.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [38] Pierre Fabre and its Partner Array BioPharma announce the Interim Results of the BEACON CRC Study with Encorafenib plus Binimetinib plus Cetuximab for the Treatment of BRAFV600E-mutant metastatic Colon Cancer (mCRC)
    不详
    [J]. VISCERAL MEDICINE, 2019, 35 (05) : 330 - 330
  • [39] SEAMARK: Randomized phase 2 study of pembrolizumab plus encorafenib plus cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E-mutant microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
    Kopetz, Scott
    Bekaii-Saab, Tanios S.
    Yoshino, Takayuki
    Chung, Chin-Hee
    Zhang, Xiaosong
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS268 - TPS268
  • [40] BEACON CRC (binimetinib [BIM], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)ICTX with
    Huijberts, Sanne
    Schellens, Jan H. M.
    Fakih, Marwan
    Peeters, Marc
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Desai, Jayesh
    Ciardiello, Fortunato
    Yoshino, Takayuki
    Maharry, Kati
    Gollerkeri, Ashwin
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345